OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
The successful human papillomavirus (HPV) and hepatitis B virus (HBV) subunit vaccines contain single viral proteins that represent 22% and 12%, respectively, of the total antigens encoded by these simple viruses. The herpes simplex virus 2 (HSV-2) genome is 20 and 50 times larger, respectively. Thus, single protein subunit vaccines represent only 1% of HSV-2’s total antigenic breadth. The concept of antigenic breadth offers a unifying explanation for why HSV-2 glycoprotein D subunit vaccines have repeatedly failed in human clinical trials, and why live HSV-2 vaccines that encode 99% of HSV-2’s antigens are more effective in side-by-side tests. We believe that live HSV-2 vaccines represent an unexplored opportunity to stop the genital herpes epidemic.
